Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications
- PMID: 36460875
- PMCID: PMC9971082
- DOI: 10.1007/s00415-022-11491-3
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications
Abstract
Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterized by motor and non-motor disturbances as a result of a complex and not fully understood pathogenesis, probably including neuroinflammation, oxidative stress, and formation of alpha-synuclein (α-syn) aggregates. As age is the main risk factor for several neurodegenerative disorders including PD, progressive aging of the immune system leading to inflammaging and immunosenescence may contribute to neuroinflammation leading to PD onset and progression; abnormal α-syn aggregation in the context of immune dysfunction may favor activation of nucleotide-binding oligomerization domain-like receptor (NOD) family pyrin domain containing 3 (NLRP3) inflammasome within microglial cells through interaction with toll-like receptors (TLRs). This process would further lead to activation of Caspase (Cas)-1, and increased production of pro-inflammatory cytokines (PC), with subsequent impairment of mitochondria and damage to dopaminergic neurons. All these phenomena are mediated by the translocation of nuclear factor kappa-B (NF-κB) and enhanced by reactive oxygen species (ROS). To date, drugs to treat PD are mainly aimed at relieving clinical symptoms and there are no disease-modifying options to reverse or stop disease progression. This review outlines the role of the TLR/NLRP3/Cas-1 pathway in PD-related immune dysfunction, also focusing on specific therapeutic options that might be used since the early stages of the disease to counteract neuroinflammation and immune dysfunction.
Keywords: Inflammation; Innate immunity; Parkinson’s disease; TLR/NLRP3/Caspase-1 pathway; Toll-like receptors; α-synuclein.
© 2022. The Author(s).
Conflict of interest statement
All authors declare no conflict of interest to disclose and that the presented work has not been previously published and is not under consideration for publication in another journal.
Figures

Similar articles
-
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.Front Immunol. 2021 Oct 8;12:719807. doi: 10.3389/fimmu.2021.719807. eCollection 2021. Front Immunol. 2021. PMID: 34691027 Free PMC article. Review.
-
NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.J Cell Mol Med. 2023 Jul;27(13):1775-1789. doi: 10.1111/jcmm.17784. Epub 2023 May 21. J Cell Mol Med. 2023. PMID: 37210624 Free PMC article. Review.
-
Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.Balkan Med J. 2022 Sep 9;39(5):318-333. doi: 10.4274/balkanmedj.galenos.2022.2022-7-100. Epub 2022 Aug 29. Balkan Med J. 2022. PMID: 36036436 Free PMC article.
-
MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.Mol Neurodegener. 2016 Apr 16;11:28. doi: 10.1186/s13024-016-0094-3. Mol Neurodegener. 2016. PMID: 27084336 Free PMC article.
-
Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.Front Immunol. 2021 Dec 1;12:794770. doi: 10.3389/fimmu.2021.794770. eCollection 2021. Front Immunol. 2021. PMID: 34925379 Free PMC article.
Cited by
-
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.Curr Neuropharmacol. 2024;22(6):1080-1109. doi: 10.2174/1570159X22666231017141636. Curr Neuropharmacol. 2024. PMID: 37898823 Free PMC article.
-
Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF/TNFR1 axis.Cell Commun Signal. 2025 Jan 6;23(1):6. doi: 10.1186/s12964-024-02017-7. Cell Commun Signal. 2025. PMID: 39762835 Free PMC article.
-
"Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.Antibiotics (Basel). 2024 Dec 4;13(12):1176. doi: 10.3390/antibiotics13121176. Antibiotics (Basel). 2024. PMID: 39766566 Free PMC article. Review.
-
The emerging links between immunosenescence in innate immune system and neurocryptococcosis.Front Immunol. 2024 Aug 20;15:1410090. doi: 10.3389/fimmu.2024.1410090. eCollection 2024. Front Immunol. 2024. PMID: 39229268 Free PMC article. Review.
-
Loganic Acid Alleviates the Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson's Disease.J Neuroimmune Pharmacol. 2025 Feb 12;20(1):19. doi: 10.1007/s11481-025-10183-9. J Neuroimmune Pharmacol. 2025. PMID: 39934492
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous